TABLE 2.
Univariate Cox Regression Analysis for Recurrence-Free Survival and Distant Metastasis-Free Survival Outcomes
| Variable | Recurrence-free survival | Distant metastasis-free survival |
|||
|---|---|---|---|---|---|
| HR (95% CI) |
P Value |
HR (95% CI) | P | ||
| Value | |||||
| Age | 0.96 (0.91, 1.01) | 0.16 | 0.98 (0.93, 1.04) | 0.69 | |
| Menopause | |||||
| Premenopausal | 1 | — | 1 | — | |
| Postmenopausal | 0.38 (0.12, 1.19) | 0.09 | 0.64 (0.19, 2.14) | 0.47 | |
| Surgery method | |||||
| Breast conserving surgery | 1 | — | 1 | — | |
| Total mastectomy | 4.23 (1.61, 11.11) | 0.003 | 4.09 (1.30, 12.90) | 0.01 | |
| Pathologic size of invasiveness | 1.05 (1.01, 1.09) | 0.004 | 1.05 (1.00, 1.10) | 0.03 | |
| Pathologic type | |||||
| IDC | 1 | — | 1 | — | |
| Non-IDC | 1.42 (0.46, 4.37) | 0.53 | 0.40 (0.05, 3.11) | 0.38 | |
| Histologic grade group | |||||
| Low | 1 | — | 1 | — | |
| High | 1.67 (0.54, 5.14) | 0.36 | 1.08 (0.23, 4.93) | 0.92 | |
| Lymphovascular invasion | |||||
| No | 1 | — | 1 | — | |
| Yes | 2.68 (0.87, 8.23) | 0.08 | 1.66 (0.36, 7.60) | 0.51 | |
| Ki-67 levela | |||||
| Low | 1 | — | 1 | — | |
| High | 6.24 (2.03, 19.16) | 0.001 | 3.73 (1.12, 12.39) | 0.03 | |
| Radiation therapy | |||||
| No | 1 | — | 1 | — | |
| Yes | 0.49 (0.19, 1.28) | 0.15 | 0.31 (0.09, 0.97) | 0.04 | |
| Adjuvant chemotherapy | |||||
| No | 1 | 1 | |||
| Yes | 2.20 (0.77, 6.25) | 0.13 | 2.75 (0.74, 10.16) | 0.12 | |
| Fibroglandular tissue | |||||
| Almost entirely fat/ Scattered FGT | 1 | — | 1 | — | |
| Heterogeneous FGT / Extreme FGT | 1.07 (0.37, 3.05) | 0.89 | 0.61 (0.19, 1.93) | 0.40 | |
| Qualitative BPE | |||||
| Reader 1 | Minimal / Mild | 1 | — | 1 | - |
| Moderate / Marked | 0.83 (0.27, 2.56) | 0.75 | 0.53 (0.11, 2.44) | 0.41 | |
| Reader 2 | Minimal / Mild | 1 | — | 1 | - |
| Moderate / Marked | 0.95 (0.35, 2.57) | 0.92 | 0.33 (0.07, 1.54) | 0.16 | |
| Quantitative BPE | |||||
| Early enhancement rate | Reader 1 | 1.00 (0.98, 1.01) | 0.96 | 0.99 (0.97, 1.01) | 0.68 |
| Reader 2 | 1.00 (0.98, 1.01) | 0.99 | 0.99 (0.97, 1.01) | 0.81 | |
| Delayed enhancement rate | Reader 1 | 1.00 (0.99, 1.01) | 0.57 | 0.99 (0.98, 1.01) | 0.89 |
| Reader 2 | 1.00 (0.98–1.01) | 0.93 | 0.99 (0.98, 1.01) | 0.94 | |
| Late enhancement | Reader 1 | 1.46 (0.07, 27.66) | 0.79 | 0.83 (0.02, 31.80) | 0.92 |
| Reader 2 | 0.61 (0.02, 16.50) | 0.77 | 0.98 (0.02, 46.74) | 0.99 | |
| SER | Reader 1 | 1.00 (0.99, 1.00) | 0.94 | 1.00 (0.99, 1.00) | 0.94 |
| Reader 2 | 1.19 (0.07, 19.79) | 0.90 | 0.70 (0.06, 8.27) | 0.77 | |
| LE90+ | 1.00 (0.99, 1.02) | 0.38 | 1.01 (0.99, 1.02) | 0.18 | |
FGT, fibroglandular tissue; BPE, background parenchymal enhancement; SER, signal enhancement ratio; LE90+, mean of the top 10% of late enhancement; HR, hazard ratio; CI, confidence interval.
a
Low; < 14, High; ≥ 14.